Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (13781)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 28, 2015 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang J, Xu ZW, Liu S, Zhang RY, Ding SL, Xie XM, Long L, Chen XM, Zhuang H, Lu FM. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World J Gastroenterol 2015; 21(32): 9554-9565 [PMID: 26327763 DOI: 10.3748/wjg.v21.i32.9554] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i32/9554.htm |
| Number | Citing Articles |
| 1 |
An-Qi Zhuang, Yan Chen, Shan-Mei Chen, Wen-Cheng Liu, Yao Li, Wen-Jie Zhang, Yi-Hang Wu. Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA. Viruses 2023; 15(12): 2315 doi: 10.3390/v15122315
|
| 2 |
Aryn A. Price, Arash Grakoui, David S. Weiss. Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense. Trends in Microbiology 2016; 24(4): 294 doi: 10.1016/j.tim.2016.01.005
|
| 3 |
P Arbuthnot, M B Maepa, A Ely, M S Pepper. The state of gene therapy research in Africa, its significance and implications for the future. Gene Therapy 2017; 24(9): 581 doi: 10.1038/gt.2017.57
|
| 4 |
Catherine A. Freije, Pardis C. Sabeti. Detect and destroy: CRISPR-based technologies for the response against viruses. Cell Host & Microbe 2021; 29(5): 689 doi: 10.1016/j.chom.2021.04.003
|
| 5 |
Shuliang Chen, Xiao Yu, Deyin Guo. CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy. Viruses 2018; 10(1): 40 doi: 10.3390/v10010040
|
| 6 |
Huafeng Lin, Gang Li, Xiangwen Peng, Aimin Deng, Lei Ye, Lei Shi, Tuanmei Wang, Jun He. The Use of CRISPR/Cas9 as a Tool to Study Human Infectious Viruses. Frontiers in Cellular and Infection Microbiology 2021; 11 doi: 10.3389/fcimb.2021.590989
|
| 7 |
Margarita A. Sazonova, Anastasia I. Ryzhkova, Vasily V. Sinyov, Marina D. Sazonova, Zukhra B. Khasanova, Nadezhda A. Nikitina, Vasily P. Karagodin, Alexander N. Orekhov, Igor A. Sobenin. Creation of Cultures Containing Mutations Linked with Cardiovascular Diseases using Transfection and Genome Editing. Current Pharmaceutical Design 2019; 25(6): 693 doi: 10.2174/1381612825666190329121532
|
| 8 |
Kristie Bloom, Mohube Maepa, Abdullah Ely, Patrick Arbuthnot. Gene Therapy for Chronic HBV—Can We Eliminate cccDNA?. Genes 2018; 9(4): 207 doi: 10.3390/genes9040207
|
| 9 |
Man Teng, Yongxiu Yao, Venugopal Nair, Jun Luo. Latest Advances of Virology Research Using CRISPR/Cas9-Based Gene-Editing Technology and Its Application to Vaccine Development. Viruses 2021; 13(5): 779 doi: 10.3390/v13050779
|
| 10 |
Mohammad Enamul Hoque Kayesh, Yutaka Amako, Md Abul Hashem, Shuko Murakami, Shintaro Ogawa, Naoki Yamamoto, Tatsuro Hifumi, Noriaki Miyoshi, Masaya Sugiyama, Yasuhito Tanaka, Masashi Mizokami, Michinori Kohara, Kyoko Tsukiyama-Kohara. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA. Virus Research 2020; 290: 198191 doi: 10.1016/j.virusres.2020.198191
|
| 11 |
Tetsushi Sakuma, Keiichi Masaki, Hiromi Abe‐Chayama, Keiji Mochida, Takashi Yamamoto, Kazuaki Chayama. Highly multiplexed CRISPR‐Cas9‐nuclease and Cas9‐nickase vectors for inactivation of hepatitis B virus. Genes to Cells 2016; 21(11): 1253 doi: 10.1111/gtc.12437
|
| 12 |
Frank Buchholz, Joachim Hauber. Antiviral therapy of persistent viral infection using genome editing. Current Opinion in Virology 2016; 20: 85 doi: 10.1016/j.coviro.2016.09.012
|
| 13 |
Jasper Adriaan Soppe, Robert Jan Lebbink. Antiviral Goes Viral: Harnessing CRISPR/Cas9 to Combat Viruses in Humans. Trends in Microbiology 2017; 25(10): 833 doi: 10.1016/j.tim.2017.04.005
|
| 14 |
Hao Li, Chunyu Sheng, Hongbo Liu, Shan Wang, Jiangyun Zhao, Lang Yang, Leili Jia, Peng Li, Ligui Wang, Jing Xie, Dongping Xu, Yansong Sun, Shaofu Qiu, Hongbin Song. Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9. Frontiers in Immunology 2018; 9 doi: 10.3389/fimmu.2018.02080
|
| 15 |
Wei-Xin Chin, Swee Kim Ang, Justin Jang Hann Chu. Recent advances in therapeutic recruitment of mammalian RNAi and bacterial CRISPR-Cas DNA interference pathways as emerging antiviral strategies. Drug Discovery Today 2017; 22(1): 17 doi: 10.1016/j.drudis.2016.08.008
|
| 16 |
Robert Jan Lebbink, Dorien C. M. de Jong, Femke Wolters, Elisabeth M. Kruse, Petra M. van Ham, Emmanuel J. H. J. Wiertz, Monique Nijhuis. A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Scientific Reports 2017; 7(1) doi: 10.1038/srep41968
|
| 17 |
Cheng Peng, Mengji Lu, Dongliang Yang. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV. Virologica Sinica 2015; 30(5): 317 doi: 10.1007/s12250-015-3660-x
|
| 18 |
Timothy Dreyer, Samantha Nicholson, Abdullah Ely, Patrick Arbuthnot, Kristie Bloom. Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus. Biochemical and Biophysical Research Communications 2016; 478(4): 1563 doi: 10.1016/j.bbrc.2016.08.152
|
| 19 |
Buhle Moyo, Kristie Bloom, Tristan Scott, Abdullah Ely, Patrick Arbuthnot. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Research 2018; 244: 311 doi: 10.1016/j.virusres.2017.01.003
|
| 20 |
Romina Salpini, Stefano D’Anna, Livia Benedetti, Lorenzo Piermatteo, Upkar Gill, Valentina Svicher, Patrick T. F. Kennedy. Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.972687
|
| 21 |
Daniel Stone, Kelly R. Long, Michelle A. Loprieno, Harshana S. De Silva Feelixge, Elizabeth J. Kenkel, R. Matt Liley, Stephen Rapp, Pavitra Roychoudhury, Thuy Nguyen, Laurence Stensland, Rossana Colón-Thillet, Lindsay M. Klouser, Nicholas D. Weber, Connie Le, Jessica Wagoner, Erin A. Goecker, Alvason Zhenhua Li, Karsten Eichholz, Lawrence Corey, D. Lorne Tyrrell, Alexander L. Greninger, Meei-Li Huang, Stephen J. Polyak, Martine Aubert, John E. Sagartz, Keith R. Jerome. CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. Molecular Therapy - Methods & Clinical Development 2021; 20: 258 doi: 10.1016/j.omtm.2020.11.014
|
| 22 |
Sandra Phillips, Ravi Jagatia, Shilpa Chokshi. Novel therapeutic strategies for chronic hepatitis B. Virulence 2022; 13(1): 1111 doi: 10.1080/21505594.2022.2093444
|
| 23 |
Fengping Jiao, Congle Shen, Jing Ning, Ting Zhang, Xiangmei Chen, Fengmin Lu. HBV T1719G mutation reduced HBV replication through mutant Enh II and HBx protein in vitro. Journal of Viral Hepatitis 2019; 26(6): 710 doi: 10.1111/jvh.13070
|
| 24 |
Zhen Wang, Qinghua Pan, Patrick Gendron, Weijun Zhu, Fei Guo, Shan Cen, Mark A. Wainberg, Chen Liang. CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. Cell Reports 2016; 15(3): 481 doi: 10.1016/j.celrep.2016.03.042
|
| 25 |
Hao Li, Chunyu Sheng, Shan Wang, Lang Yang, Yuan Liang, Yong Huang, Hongbo Liu, Peng Li, Chaojie Yang, Xiaoxia Yang, Leili Jia, Jing Xie, Ligui Wang, Rongzhang Hao, Xinying Du, Dongping Xu, Jianjun Zhou, Mingzhen Li, Yansong Sun, Yigang Tong, Qiao Li, Shaofu Qiu, Hongbin Song. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9. Frontiers in Cellular and Infection Microbiology 2017; 7 doi: 10.3389/fcimb.2017.00091
|
| 26 |
Antara Barman, Bornali Deb, Supriyo Chakraborty. A glance at genome editing with CRISPR–Cas9 technology. Current Genetics 2020; 66(3): 447 doi: 10.1007/s00294-019-01040-3
|
| 27 |
Lulia Koujah, Deepak Shukla, Afsar R. Naqvi. CRISPR-Cas based targeting of host and viral genes as an antiviral strategy. Seminars in Cell & Developmental Biology 2019; 96: 53 doi: 10.1016/j.semcdb.2019.04.004
|
| 28 |
Takehisa Watanabe, Sanae Hayashi, Yasuhito Tanaka. Drug Discovery Study Aimed at a Functional Cure for HBV. Viruses 2022; 14(7): 1393 doi: 10.3390/v14071393
|
| 29 |
Wanjia Zeng, Liwei Zheng, Yukun Li, Jing Yang, Tianhao Mao, Jing Zhang, Yanna Liu, Jing Ning, Ting Zhang, Hongxin Huang, Xiangmei Chen, Fengmin Lu. Engineered extracellular vesicles for delivering functional Cas9/gRNA to eliminate hepatitis B virus cccDNA and integration. Emerging Microbes & Infections 2024; 13(1) doi: 10.1080/22221751.2023.2284286
|
| 30 |
Dmitry Kostyushev, Anastasiya Kostyusheva, Natalia Ponomareva, Sergey Brezgin, Vladimir Chulanov. CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers. Nucleic Acid Therapeutics 2022; 32(1): 14 doi: 10.1089/nat.2021.0075
|
| 31 |
Chiaho Shih, Shu-Fan Chou, Ching-Chun Yang, Jyun-Yuan Huang, Gansukh Choijilsuren, Ren-Shiang Jhou. Control and Eradication Strategies of Hepatitis B Virus. Trends in Microbiology 2016; 24(9): 739 doi: 10.1016/j.tim.2016.05.006
|
| 32 |
Dan Wang, Ling Chen, Chengbi Li, Quanxin Long, Qing Yang, Ailong Huang, Hua Tang. CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy. Journal of Nanobiotechnology 2022; 20(1) doi: 10.1186/s12951-021-01233-4
|
| 33 |
Iman Ibrahim Salama, Samia M Sami, Somaia I Salama, Ghada A Abdel-Latif, Fatma A Shaaban, Walaa A Fouad, Aida M Abdelmohsen, Hala M Raslan. Current and novel modalities for management of chronic hepatitis B infection. World Journal of Hepatology 2023; 15(5): 585-608 doi: 10.4254/wjh.v15.i5.585
Abstract(372) |
Core Tip(264) |
Full Article(HTML)(2315)
|
Full Article with Cover (PDF)-3003K(112)
|
Full Article (Word)-511K(26)
|
Audio-567K(3)
|
Peer-Review Report-323K(25)
|
Answering Reviewers-310K(25)
|
Full Article (PDF)-1702K(170)
|
Full Article (XML)-450K(22)
|
Times Cited (1)
|
Total Visits (4666)
|
Open
|
| 34 |
Muhammad Naeem, Hanoof Fahd Alkhodairy, Iqra Ashraf, Amjad Bajes Khalil. CRISPR/Cas System Toward the Development of Next-Generation Recombinant Vaccines: Current Scenario and Future Prospects. Arabian Journal for Science and Engineering 2023; 48(1): 1 doi: 10.1007/s13369-022-07266-7
|
| 35 |
|
| 36 |
Chia-Chen Chen, Guiwen Guan, Xuewei Qi, Abudurexiti Abulaiti, Ting Zhang, Jia Liu, Fengmin Lu, Xiangmei Chen. Pacbio Sequencing of PLC/PRF/5 Cell Line and Clearance of HBV Integration Through CRISPR/Cas-9 System. Frontiers in Molecular Biosciences 2021; 8 doi: 10.3389/fmolb.2021.676957
|
| 37 |
Jesse A. Weber, Jonathan F. Lang, Ellie M. Carrell, Mohamad-Gabriel Alameh, Beverly L. Davidson. Temporal restriction of Cas9 expression improves CRISPR-mediated deletion efficacy and fidelity. Molecular Therapy - Nucleic Acids 2024; 35(2): 102172 doi: 10.1016/j.omtn.2024.102172
|
| 38 |
Guigao Lin, Kuo Zhang, Jinming Li. Application of CRISPR/Cas9 Technology to HBV. International Journal of Molecular Sciences 2015; 16(11): 26077 doi: 10.3390/ijms161125950
|
| 39 |
Shyam Tripathi, Purnima Khatri, Zeeshan Fatima, Ramendra Pati Pandey, Saif Hameed. A Landscape of CRISPR/Cas Technique for Emerging Viral Disease Diagnostics and Therapeutics: Progress and Prospects. Pathogens 2022; 12(1): 56 doi: 10.3390/pathogens12010056
|
| 40 |
Edward M. Kennedy, Anand V.R. Kornepati, Bryan R. Cullen. Targeting hepatitis B virus cccDNA using CRISPR/Cas9. Antiviral Research 2015; 123: 188 doi: 10.1016/j.antiviral.2015.10.004
|
| 41 |
Jie Wang, Tao Shen, Xiangbo Huang, G. Renuka Kumar, Xiangmei Chen, Zhenzhen Zeng, Ruiyang Zhang, Ran Chen, Tong Li, Tianying Zhang, Quan Yuan, Pao-Chen Li, Qi Huang, Richard Colonno, Jidong Jia, Jinlin Hou, Malcolm A. McCrae, Zhiliang Gao, Hong Ren, Ningshao Xia, Hui Zhuang, Fengmin Lu. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. Journal of Hepatology 2016; 65(4): 700 doi: 10.1016/j.jhep.2016.05.029
|
| 42 |
Dmitry Kostyushev, Anastasiya Kostyusheva, Sergey Brezgin, Natalia Ponomareva, Natalia F. Zakirova, Aleksandra Egorshina, Dmitry V. Yanvarev, Ekaterina Bayurova, Anna Sudina, Irina Goptar, Anastasiya Nikiforova, Elena Dunaeva, Tatiana Lisitsa, Ivan Abramov, Anastasiia Frolova, Alexander Lukashev, Ilya Gordeychuk, Andrey A. Zamyatnin, Alexander Ivanov, Vladimir Chulanov. Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9. Molecular Therapy - Nucleic Acids 2023; 31: 482 doi: 10.1016/j.omtn.2023.02.001
|
| 43 |
Xianlong Wang, Chunwei Cao, Jiaojiao Huang, Jing Yao, Tang Hai, Qiantao Zheng, Xiao Wang, Hongyong Zhang, Guosong Qin, Jinbo Cheng, Yanfang Wang, Zengqiang Yuan, Qi Zhou, Hongmei Wang, Jianguo Zhao. One-step generation of triple gene-targeted pigs using CRISPR/Cas9 system. Scientific Reports 2016; 6(1) doi: 10.1038/srep20620
|
| 44 |
Martyn K. White, Kamel Khalili. CRISPR/Cas9 and cancer targets: future possibilities and present challenges. Oncotarget 2016; 7(11): 12305 doi: 10.18632/oncotarget.7104
|
| 45 |
Daniel Stone, Nixon Niyonzima, Keith R. Jerome. Genome editing and the next generation of antiviral therapy. Human Genetics 2016; 135(9): 1071 doi: 10.1007/s00439-016-1686-2
|
| 46 |
Congle Shen, Yongzhen Liu, Shu Shi, Ruiyang Zhang, Ting Zhang, Qiang Xu, Pengfei Zhu, Xiangmei Chen, Fengmin Lu. Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region upregulating the allele-specific MYC expression in HeLa cells. International Journal of Cancer 2017; 141(3): 540 doi: 10.1002/ijc.30763
|
| 47 |
Gang Wang, Na Zhao, Ben Berkhout, Atze T Das. CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape. Molecular Therapy 2016; 24(3): 522 doi: 10.1038/mt.2016.24
|
| 48 |
Abdullah Ely, Buhle Moyo, Patrick Arbuthnot. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus. Molecular Therapy 2016; 24(4): 671 doi: 10.1038/mt.2016.43
|
| 49 |
Jia Song, Xiaochao Zhang, Qianyun Ge, Chaoyi Yuan, Liang Chu, Hui‐fang Liang, Zhibin Liao, Qiumeng Liu, Zhanguo Zhang, Bixiang Zhang. CRISPR/Cas9‐mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV‐positive hepatocellular carcinoma cells. Journal of Cellular Biochemistry 2018; 119(10): 8419 doi: 10.1002/jcb.27050
|
| 50 |
Xinjie Wang, Yanhua Li, Xingxu Huang. Molecular Medical Microbiology. 2024; : 2039 doi: 10.1016/B978-0-12-818619-0.00077-0
|
| 51 |
Saeedeh Ebrahimi, Ali Teimoori, Hashem Khanbabaei, Maryam Tabasi. Harnessing CRISPR/Cas 9 System for manipulation of DNA virus genome. Reviews in Medical Virology 2019; 29(1) doi: 10.1002/rmv.2009
|
| 52 |
Dmitry Kostyushev, Sergey Brezgin, Anastasiya Kostyusheva, Dmitry Zarifyan, Irina Goptar, Vladimir Chulanov. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus. Cellular and Molecular Life Sciences 2019; 76(9): 1779 doi: 10.1007/s00018-019-03021-8
|
| 53 |
Bin Liu, Ali Saber, Hidde J. Haisma. CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment. Drug Discovery Today 2019; 24(4): 955 doi: 10.1016/j.drudis.2019.02.011
|
| 54 |
Congle Shen, Xiaoyu Feng, Tianhao Mao, Danli Yang, Jun Zou, Xiaobin Zao, Qiang Deng, Xiangmei Chen, Fengmin Lu. Yin-Yang 1 and HBx protein activate HBV transcription by mediating the spatial interaction of cccDNA minichromosome with cellular chromosome 19p13.11. Emerging Microbes & Infections 2020; 9(1): 2455 doi: 10.1080/22221751.2020.1840311
|
| 55 |
Yu Xiang, Yang Yang, Pu Chen, Xiaofei Lai, Shan Shi, Shuang Li, Wenxian You. Analysis of serum hepatitis B virus RNA levels among HBsAg and HBsAb copositive patients and its correlation with HBV DNA. Medicine 2021; 100(40): e27433 doi: 10.1097/MD.0000000000027433
|
| 56 |
Dmitry Kostyushev, Anastasiya Kostyusheva, Sergey Brezgin, Dmitry Zarifyan, Anastasiya Utkina, Irina Goptar, Vladimir Chulanov. Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-38526-6
|
| 57 |
Maria Guadalupe Martinez, Elena Smekalova, Emmanuel Combe, Francine Gregoire, Fabien Zoulim, Barbara Testoni. Gene Editing Technologies to Target HBV cccDNA. Viruses 2022; 14(12): 2654 doi: 10.3390/v14122654
|
| 58 |
M. Doerflinger, W. Forsyth, G. Ebert, M. Pellegrini, M.J. Herold. CRISPR/Cas9-The ultimate weapon to battle infectious diseases?. Cellular Microbiology 2017; 19(2): e12693 doi: 10.1111/cmi.12693
|
| 59 |
Jie Wang, Junqiao Jia, Ran Chen, Shanlong Ding, Qiang Xu, Ting Zhang, Xiangmei Chen, Shuang Liu, Fengmin Lu. RFX1 participates in doxorubicin‐induced hepatitis B virus reactivation. Cancer Medicine 2018; 7(5): 2021 doi: 10.1002/cam4.1468
|
| 60 |
Abozar Ghorbani, Shima Hadifar, Roya Salari, Keramatollah Izadpanah, Michal Burmistrz, Alireza Afsharifar, Mohammad Hadi Eskandari, Ali Niazi, Christopher E. Denes, G. Gregory Neely. A short overview of CRISPR-Cas technology and its application in viral disease control. Transgenic Research 2021; 30(3): 221 doi: 10.1007/s11248-021-00247-w
|
| 61 |
Ran Chen, Hongxin Huang, Hui Liu, Jingyuan Xi, Jing Ning, Wanjia Zeng, Congle Shen, Ting Zhang, Guangxin Yu, Qiang Xu, Xiangmei Chen, Jie Wang, Fengmin Lu. Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein. Small 2019; 15(38) doi: 10.1002/smll.201902686
|
| 62 |
Xia Jiang, Tatsuo Kanda, Yuki Haga, Reina Sasaki, Masato Nakamura, Shuang Wu, Shingo Nakamoto, Hiroshi Shirasawa, Hiroaki Okamoto, Osamu Yokosuka. Glucose-regulated protein 78 is an antiviral against hepatitis A virus replication. Experimental and Therapeutic Medicine 2017; 13(6): 3305 doi: 10.3892/etm.2017.4407
|
| 63 |
Ridhwaanah Jacobs, Prashika Singh, Tiffany Smith, Patrick Arbuthnot, Mohube Betty Maepa. Prospects of viral vector-mediated delivery of sequences encoding anti-HBV designer endonucleases. Gene Therapy 2022; doi: 10.1038/s41434-022-00342-5
|
| 64 |
Jie Wang, Hongxin Huang, Yongzhen Liu, Ran Chen, Ying Yan, Shu Shi, Jingyuan Xi, Jun Zou, Guangxin Yu, Xiaoyu Feng, Fengmin Lu. Hepatitis B Virus Infection. Advances in Experimental Medicine and Biology 2020; 1179: 17 doi: 10.1007/978-981-13-9151-4_2
|
| 65 |
Martyn K. White, Wenhui Hu, Kamel Khalili, Carolyn B Coyne. Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape. PLOS Pathogens 2016; 12(12): e1005953 doi: 10.1371/journal.ppat.1005953
|
| 66 |
Wen-Hsuan Wu, Yi-Ting Tsai, I-Wen Huang, Chia-Hua Cheng, Chun-Wei Hsu, Xuan Cui, Joseph Ryu, Peter M.J. Quinn, Salvatore Marco Caruso, Chyuang-Sheng Lin, Stephen H. Tsang. CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa. Molecular Therapy 2022; 30(4): 1407 doi: 10.1016/j.ymthe.2022.02.010
|
| 67 |
Abdullah Ely, Prashika Singh, Tiffany S. Smith, Patrick Arbuthnot. In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection. Advanced Drug Delivery Reviews 2021; 168: 134 doi: 10.1016/j.addr.2020.05.010
|
| 68 |
Carmen Escalona‐Noguero, María López‐Valls, Begoña Sot. CRISPR/Cas technology as a promising weapon to combat viral infections. BioEssays 2021; 43(4) doi: 10.1002/bies.202000315
|
| 69 |
Santosh Bhujbal, Rushikesh Bhujbal, Prabhanjan Giram. An overview: CRISPR/Cas-based gene editing for viral vaccine development. Expert Review of Vaccines 2022; 21(11): 1581 doi: 10.1080/14760584.2022.2112952
|
| 70 |
Amal Senevirathne, Chamith Hewawaduge, John Hwa Lee. Genetic interference exerted by Salmonella-delivered CRISPR/Cas9 significantly reduces the pathological burden caused by Marek’s disease virus in chickens. Veterinary Research 2021; 52(1) doi: 10.1186/s13567-021-00995-x
|
| 71 |
Hao Li, Shan Wang, Xue Dong, Qiao Li, Min Li, Junfeng Li, Yan Guo, Xia Jin, Yusen Zhou, Hongbin Song, Zhihua Kou. CRISPR-Cas13a Cleavage of Dengue Virus NS3 Gene Efficiently Inhibits Viral Replication. Molecular Therapy - Nucleic Acids 2020; 19: 1460 doi: 10.1016/j.omtn.2020.01.028
|
| 72 |
Mohammad Enamul Hoque Kayesh, Md Abul Hashem, Michinori Kohara, Kyoko Tsukiyama-Kohara. In vivo Delivery Tools for Clustered Regularly Interspaced Short Palindromic Repeat/Associated Protein 9-Mediated Inhibition of Hepatitis B Virus Infection: An Update. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.953218
|
| 73 |
Choongho Lee. CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge. Molecules 2019; 24(7): 1349 doi: 10.3390/molecules24071349
|
| 74 |
Rodolphe Barrangou, Jennifer A Doudna. Applications of CRISPR technologies in research and beyond. Nature Biotechnology 2016; 34(9): 933 doi: 10.1038/nbt.3659
|
| 75 |
Yu-Chan Yang, Hung-Chih Yang. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas. Viruses 2021; 14(1): 4 doi: 10.3390/v14010004
|
| 76 |
Kai O. Hensel, Julio C. Rendon, Maria‐Cristina Navas, Marianne G. Rots, Jan Postberg. Virus–host interplay in hepatitis B virus infection and epigenetic treatment strategies. The FEBS Journal 2017; 284(21): 3550 doi: 10.1111/febs.14094
|
| 77 |
Usman Gilani, Memoona Shaukat, Arisha Rasheed, Mehak Shahid, Fareeda Tasneem, Muhammad Arshad, Naeem Rashid, Naveed Shahzad. The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses. Journal of Medical Virology 2019; 91(1): 1 doi: 10.1002/jmv.25292
|
| 78 |
Shuye Zhang, Fusheng Wang, Zheng Zhang. Current advances in the elimination of hepatitis B in China by 2030. Frontiers of Medicine 2017; 11(4): 490 doi: 10.1007/s11684-017-0598-4
|
| 79 |
Liudi Tang, Qiong Zhao, Shuo Wu, Junjun Cheng, Jinhong Chang, Ju-Tao Guo. The current status and future directions of hepatitis B antiviral drug discovery. Expert Opinion on Drug Discovery 2017; 12(1): 5 doi: 10.1080/17460441.2017.1255195
|
| 80 |
Henrik Zhang, Thomas Tu. Targeting Hepatitis B Virus DNA Using Designer Gene Editors. Clinics in Liver Disease 2023; 27(4): 895 doi: 10.1016/j.cld.2023.05.006
|
| 81 |
Wattana Leowattana, Tawithep Leowattana. Chronic hepatitis B: New potential therapeutic drugs target. World Journal of Virology 2022; 11(1): 57-72 doi: 10.5501/wjv.v11.i1.57
|
| 82 |
Magda Rybicka, Krzysztof Piotr Bielawski. Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection. Microorganisms 2020; 8(9): 1416 doi: 10.3390/microorganisms8091416
|
| 83 |
Ridhwaanah Jacobs, Makafui Dennis Dogbey, Njabulo Mnyandu, Keila Neves, Stefan Barth, Patrick Arbuthnot, Mohube Betty Maepa. AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy. Microorganisms 2023; 11(12): 2985 doi: 10.3390/microorganisms11122985
|
| 84 |
Kazuto Tajiri, Yukihiro Shimizu. New horizon for radical cure of chronic hepatitis B virus infection. World Journal of Hepatology 2016; 8(21): 863-873 doi: 10.4254/wjh.v8.i21.863
|
| 85 |
Maria Guadalupe Martinez, Emmanuel Combe, Aurore Inchauspe, Philippe Emmanuel Mangeot, Elodie Delberghe, Fleur Chapus, Gregory Neveu, Antoine Alam, Kara Carter, Barbara Testoni, Fabien Zoulim, Jianming Hu, Monica J. Roth. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants. mBio 2022; 13(2) doi: 10.1128/mbio.02888-21
|
| 86 |
Raymond F. Schinazi, Maryam Ehteshami, Leda Bassit, Tarik Asselah. Towards HBV curative therapies. Liver International 2018; 38(S1): 102 doi: 10.1111/liv.13656
|
| 87 |
Sajad Najafi, Shing Cheng Tan, Shahin Aghamiri, Pourya Raee, Zahra Ebrahimi, Zahra Kargar Jahromi, Yazdan Rahmati, Javid Sadri Nahand, Ahmad Piroozmand, Vahid Jajarmi, Hamed Mirzaei. Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections. Biomedicine & Pharmacotherapy 2022; 148: 112743 doi: 10.1016/j.biopha.2022.112743
|
| 88 |
Hung-Chih Yang, Pei-Jer Chen. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Virus Research 2018; 244: 304 doi: 10.1016/j.virusres.2017.06.010
|
| 89 |
涛 颜. Research Progress in the Clinical Application of HBV RNA in Chronic Hepatitis B. Advances in Clinical Medicine 2023; 13(01): 899 doi: 10.12677/ACM.2023.131130
|
| 90 |
Lan Yu, Xun Tian, Chun Gao, Ping Wu, Liming Wang, Bei Feng, Xiaomin Li, Hui Wang, Ding Ma, Zheng Hu. Genome editing for the treatment of tumorigenic viral infections and virus-related carcinomas. Frontiers of Medicine 2018; 12(5): 497 doi: 10.1007/s11684-017-0572-1
|
| 91 |
Arinze Okoli, Malachy Okeke, Morten Tryland, Ugo Moens. CRISPR/Cas9—Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development. Viruses 2018; 10(1): 50 doi: 10.3390/v10010050
|